ESR1 and breast cancer: These differences in the AhR/ERα pathway between I3C and CUR may contribute to the mechanism that with LUT in common, why LUT+I3C exclusively inhibits ER+ breast cancer, but LUT+CUR only synergistically suppresses TNBC, both in cells and xenograft mice.